Paws, Pills and Progress – CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
SynWeave™: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones.
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases.
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) have become a cornerstone in modern therapeutics, offering targeted treatment options across various diseases, including cancer, autoimmune disorders, and infectious diseases.
Selecting the right preclinical species for screening oral dosage form for PK studies
Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.
Accelerating development of a unique molecule to treat lung cancer
Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.
Developing a stable specialty polymer for use in energy applications: A collaboration with Notark
Learn how Syngene partnered with a global producer of specialty polymers to develop a novel, high-performance polymer for use in sustainable energy generation.
Overcoming analytical challenges with chemical derivatization in LC-MS/MS
Learn about the challenges in chemical derivatization and utilizing LC-MS/MS to detect and quantify trace compounds in complex molecules for supporting bioanalytical studies.
